Qi Zhang - Concepedia

Author

Qi Zhang

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Q Zhang, Qi Tatarata, Qi ZHANG, Qi Zhang, Qi Zhang Tatarata, Zhang, Qi

258

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Chinese Academy of Medical Sciences & Peking Union Medical College Harbin Medical University First Affiliated Hospital of Harbin Medical University AbbVie (United States)

About

Qi Zhang is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell biology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	22	2.2K
2	Health Sciences	6	6	171
3	Public Health	3	3	49
4	Natural Sciences	2	2	591
5	Engineering	1	1	15

Qi Zhang

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity Sajid Khan, Xuan Zhang, Dongwen Lv, Nature Medicine OncologyMedicinePotent Antitumor ActivityImmune Checkpoint InhibitorAnti-cancer Agent	2019	608
Serine ADP-Ribosylation Depends on HPF1 Juán José Bonfiglio, Pietro Fontana, Qi Zhang, Molecular Cell Serine-specific AdprReductive StressProtein FunctionBiochemistryNatural Sciences	2017	350
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials Timothy A. Yap, Naval Daver, Mikhila Mahendra, Nature Medicine Hematological MalignancyOncologyBiochemistryMedicineAcute Myeloid Leukemia	2023	335
Serine is a new target residue for endogenous ADP-ribosylation on histones Orsolya Leidecker, Juán José Bonfiglio, Thomas Colby, Nature Chemical Biology ChromatinCellular EnzymologyBiochemistryNatural SciencesMolecular Biology	2016	241
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia Qi Zhang, Bridget Riley‐Gillis, Lina Han, Signal Transduction and Targeted Therapy	2022	168
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity, Dongwen Lv, Pratik Pal, Xingui Liu, Nature Communications	2021	140
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models Raghuveer Singh Mali, Qi Zhang, RosaAnna DeFilippis, Haematologica Venetoclax MonotherapyHematological MalignancyVenetoclax CombinesLeukemic CellsMedicine	2020	134
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia Heikki Kuusanmäki, Olli Dufva, Markus Vähä‐Koskela, Blood	2022	112
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models Lina Han, Qi Zhang, Monique Dail, Haematologica	2019	111
Drug-in-cyclodextrin-in-liposomes: A novel drug delivery system for flurbiprofen Lina Zhang, Qi Zhang, Xin Wang, International Journal of Pharmaceutics NanomedicineMedicinal ChemistryMedicineCyclodextrin ProductionDrug Delivery Systems	2015	85

Page 1